Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDS Biotechnology (PDSB) Stock Price & Analysis
652 Followers
PDSB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.59 - $9.54
Previous Close$2.98
Volume411.61K
Average Volume (3M)876.64K
Market Cap
$109.30M
Enterprise Value$66.81M
Total Cash (Recent Filing)$66.60M
Total Debt (Recent Filing)$24.11M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 14, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding36,679,275
10 Day Avg. Volume464,727
30 Day Avg. Volume876,645
Standard Deviation0.34
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.91
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$17.33Price Target Upside481.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PDS Biotechnology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPDS0101, combined with pembrolizumab, demonstrates impressive efficacy in VERSATILE-002 trial updates.
Financial PerformanceThe company posted EPS of ($0.30) compared to the estimated ($0.33) and consensus of ($.37), indicating better than expected financial results.
Strategic FocusGILD’s $700M deal on Tumor-Activated IL-12 highlights the value of PDSB’s strategic focus on Triplet Therapy in HNSCC.
Bears Say
Clinical Development DelaysThere is a one-year delay to the initially planned Ph. III initiation, which could impact the stock's short-term performance.
Financial Reporting‘Going concern’ language was included in 10-Q, reflecting challenges in the biotech sector despite a cash runway guidance to 3Q24.
Stock DilutionQuarterly EPS may not add to full year due to increases in share count, indicating potential dilution for existing shareholders.
---
Ownership Overview
21.28%
Insiders
7.02% Mutual Funds
8.60% Other Institutional Investors
63.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $2.59 and its highest was $9.54 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
Currently, no data Available
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Aug 14, 2024 which is in 73 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on May 15, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.067.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -$0.34.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 36,679,276 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went down -1.13%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Among the largest hedge funds holding PDS Biotechnology Corporation’s share is New Leaf Venture Partners, L.L.C.. It holds PDS Biotechnology Corporation’s shares valued at N/A.
---
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (481.54% Upside)
$17.33 (481.54% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.89%
12-Months-Change
Fundamentals
Return on Equity
-112.25%
Trailing 12-Months
Asset Growth
0.81%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
PDSB Earnings Call
Q4 2024
0:00 / 0:00
---
PDSB Stock 12 Month Forecast
Average Price Target
$17.33
▲(481.54% Upside)
Technical Analysis
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
4/21 ratings generated profit
1 Year Average Return
-28.97%
reiterated a buy rating 2 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 19.05% of your transactions generating a profit, with an average return of -28.97% per trade.
---